Ascentage Pharma Group International

{ "date": [ "202612", "202712", "202812" ], "revenue_estimate": [ 137.53090830218048, 205.04599563647497, 956.8757416078697 ], "net_income_estimate": [ null, null, null ], "ebit_estimate": [ null, null, null ], "ebitda_estimate": [ null, null, null ], "per_share_eps_estimate": [ -0.4301006672875971, -0.2800566492721079, 1.6403664340303916 ], "eps_nri_estimate": [ -0.4301006672875971, -0.2800566492721079, 1.6403664340303916 ], "dividend_estimate": [ null, null, null ], "operating_cash_flow_per_share_estimate": [ null, null, null ], "book_value_per_share_estimate": [ null, null, null ], "pretax_income_estimate": [ null, null, null ], "roa_estimate": [ null, null, null ], "roe_estimate": [ null, null, null ], "gross_margin_estimate": [ null, null, null ], "pettm_estimate": [ 0, 0, 12.17 ], "operating_cash_flow_estimate": [ null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "57.17", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 57.17, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.72, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [], "revenue_estimate": [], "net_income_estimate": [], "ebit_estimate": [], "ebitda_estimate": [], "per_share_eps_estimate": [], "eps_nri_estimate": [], "dividend_estimate": [], "operating_cash_flow_per_share_estimate": [], "book_value_per_share_estimate": [], "pretax_income_estimate": [], "roa_estimate": [], "roe_estimate": [], "gross_margin_estimate": [], "pettm_estimate": [], "operating_cash_flow_estimate": [], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "57.17", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 57.17, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.72, "future_operating_cash_flow_per_share_estimate_growth": null }